These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 23698252

  • 1. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS.
    Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
    [Abstract] [Full Text] [Related]

  • 2. Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.
    Zhen YZ, Lin YJ, Shang BY, Zhen YS.
    Int J Hematol; 2009 Jul; 90(1):44-51. PubMed ID: 19468799
    [Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H, Wang YC, Li D, Wang Y, Liu W, Wu YL, Chen GQ.
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [Abstract] [Full Text] [Related]

  • 4. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC.
    Cancer Res; 2004 Dec 01; 64(23):8746-53. PubMed ID: 15574786
    [Abstract] [Full Text] [Related]

  • 5. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 6. [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].
    Yang J, Chen SZ.
    Yao Xue Xue Bao; 2010 Oct 01; 45(10):1247-53. PubMed ID: 21348302
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice.
    Zhen YZ, Lin YJ, Li Y, Zhen YS.
    Acta Pharmacol Sin; 2009 Jul 01; 30(7):1025-32. PubMed ID: 19575006
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
    Lou Z, Ren T, Peng X, Sun Y, Jiao G, Lu Q, Zhang S, Lu X, Guo W.
    J Int Med Res; 2013 Oct 01; 41(5):1505-19. PubMed ID: 23975859
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
    Park J, Ahn KS, Bae EK, Kim BS, Kim BK, Lee YY, Yoon SS.
    Anticancer Drugs; 2008 Sep 01; 19(8):777-82. PubMed ID: 18690088
    [Abstract] [Full Text] [Related]

  • 17. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 18. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
    Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S, Hatake K, Yamauchi A, Hirashima M, Taniwaki M.
    Leukemia; 2010 Apr 21; 24(4):843-50. PubMed ID: 20200560
    [Abstract] [Full Text] [Related]

  • 19. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA.
    Mol Cancer Ther; 2006 Sep 21; 5(9):2378-87. PubMed ID: 16985072
    [Abstract] [Full Text] [Related]

  • 20. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 21; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.